Similarly, the key enzyme inhibition potential against the clinically relevant enzymes included in the most common pathologies, i.e., neurological problems [acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)], diabetes (amylase and glucosidase), Helicobacter pylori–related infections (urease), and skin disorders (tyrosinase) was also investigated. Here, BCHE is linked to diabetes mellitus.